-
-
-
-
-
-
-
Jefferies on Axsome Therapeutics (AXSM): balipodect development rights acquisition 'adds depth to CNS pipeline'
-
-
-
-
-
-
-
Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Leerink on Axsome Therapeutics (AXSM): 'This is very positive news'
-
-
-
-
-
-
-
Axsome receives FDA feedback supporting AXS-12 narcolepsy drug filing
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
-
-
-
-
-
-
-
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against First High-School, Upstart, Oscar Health, and Axsome and Encourages Investors to Contact the Firm
-
15,557 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

